An Evaluation of a Antimicrobial Stewardship Recommendation Bundle for Staphylococcus Aureus Bloodstream Infections

January 16, 2024 updated by: Methodist Health System
In July 2020, a bundle (Appendix C) was implemented at Methodist Dallas Medical Center where all patients with SAB were reviewed by the antimicrobial stewardship pharmacist (Monday - Friday from 0700 to 1500), a note outlining optimal interventions was written in the electronic medical record (EMR), and the recommendations were communicated to the primary team via secure messaging or telephone

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

Evaluation of the Staphylococcus aureus bloodstream infection(SAB)bundle recommendations will allow for determination of whether this intervention is impactful and warrants the resources currently devoted to it.

Study Type

Observational

Enrollment (Estimated)

208

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • Dallas, Texas, United States, 75203
        • Methodist Dallas Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

18 years of age SAB during hospital admission a history of a prior SAB during the study period (only first occurrence

Description

Inclusion Criteria:

  • 18 years of age SAB during hospital admission

Exclusion Criteria:

  • Patients with a history of a prior SAB during the study period (only first occurrence included)
  • Blood culture collected within 48hours of patient expiring or transitioning to hospice
  • Patients discharged or left before culture results were available
  • Patients transferred from an outside hospital

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
number of Staphylococcus Aureus blood stream infections (SAB)
Time Frame: 12 weeks
Number of SAB occurring
12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of In-hospital mortality
Time Frame: 12 weeks
Number of In-hospital mortality
12 weeks
number of times of bacteremia
Time Frame: 12 weeks
time of bacteremia
12 weeks
number of days of stay
Time Frame: 12 weeks
duration of hospital stay
12 weeks
number of times of readmission
Time Frame: 12 weeks
Number time of readmission
12 weeks
number of infection
Time Frame: 12 weeks
Number of times the infection is occurring
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Methodist Health System

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 18, 2022

Primary Completion (Estimated)

May 18, 2024

Study Completion (Estimated)

May 18, 2024

Study Registration Dates

First Submitted

July 6, 2023

First Submitted That Met QC Criteria

January 16, 2024

First Posted (Estimated)

January 18, 2024

Study Record Updates

Last Update Posted (Estimated)

January 18, 2024

Last Update Submitted That Met QC Criteria

January 16, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 016.PHA.2022.D

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bacterial Infections

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe